Pharmaceutical

Eli Lilly strikes $1.3bn gene therapy deal with Rznomics

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

May 18, 2025 - 06:00
Eli Lilly strikes $1.3bn gene therapy deal with Rznomics
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
Read the original article

Tags:

Previous Article

HIV-1 Fusion Peptide’s Shape Shift Unlocks Envelope

Next Article

Newborn screening strategy needs modernising as HHS disbands advisory committee 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: White House drug-shortage task force brainstorms fixes; U.S. pharma layoffs are ballooning

STAT+: Pharmalittle: White House drug-shortage task for...

Aug 5, 2023

Patient comfort in AI-driven healthcare linked to familiarity with technology

Patient comfort in AI-driven healthcare linked to famil...

Oct 13, 2023

STAT+: Pharmalittle: Lilly’s Alzheimer’s drug slowed cognitive decline; most EU countries back plan to push production of key drugs

STAT+: Pharmalittle: Lilly’s Alzheimer’s drug slowed co...

May 3, 2023